BioNTech (NASDAQ:BNTX) Given New $98.00 Price Target at TD Cowen

BioNTech (NASDAQ:BNTX) had its price target increased by equities researchers at TD Cowen from $95.00 to $98.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen’s target price indicates a potential upside of 7.36% from the company’s previous close.

Several other equities analysts also recently weighed in on the company. BMO Capital Markets dropped their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday. UBS Group lowered their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $107.00 price objective on shares of BioNTech in a research report on Wednesday, April 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. Finally, The Goldman Sachs Group lowered their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $118.27.

BioNTech Price Performance

BioNTech stock traded down $2.07 during mid-day trading on Tuesday, hitting $91.28. 273,024 shares of the company were exchanged, compared to its average volume of 655,015. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The business’s 50 day simple moving average is $90.53 and its two-hundred day simple moving average is $95.99. The company has a market capitalization of $21.70 billion, a P/E ratio of 22.07 and a beta of 0.25. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Analysts forecast that BioNTech will post -1.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. boosted its holdings in BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after acquiring an additional 86,343 shares during the last quarter. Primecap Management Co. CA boosted its holdings in BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Harding Loevner LP acquired a new position in shares of BioNTech during the fourth quarter worth about $410,984,000. Flossbach Von Storch AG lifted its stake in shares of BioNTech by 1.0% during the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after purchasing an additional 35,445 shares in the last quarter. Finally, Capital World Investors lifted its stake in shares of BioNTech by 1.5% during the fourth quarter. Capital World Investors now owns 938,747 shares of the company’s stock worth $99,075,000 after purchasing an additional 14,027 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.